A randomized, double-blind, placebo-controlled, cross-over trial to evaluate the effect of EstroSense on 2-hydroxyestrone:16α-hydroxyestrone ratio in premenopausal women.

Objectives: Some estrogen metabolites are associated with increased breast cancer risk, while others are protective. Research efforts have focused on modifiable factors, including bioactive compounds found in food or supplements, promoting estrogen profiles with anti-cancer properties. EstroSense is a nutraceutical product with bioactive compounds, including Indole-3-carbinol and green-tea catechins, which may favourably affect estrogen profiles.